The role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
The role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
批准号:
10573956
负责人:
Panagiotis Koutakis
金额:
$13.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-15 至 2024-03-31
关键词:
AffectAgeAge-YearsAmericanBindingBypassCell RespirationDiagnosisDisease ProgressionFunctional disorderGastrocnemius MuscleGene ExpressionGenerationsHindlimbHomologous GeneHyperoxiaHypoxiaImpairmentIn VitroIronIschemiaLaboratoriesMessenger RNAMicroRNAsMitochondriaModelingNucleotidesOxidative StressPatientsPeripheral arterial diseaseProceduresPrognosisProteinsProtocols documentationQuality of lifeRegulator GenesRoleSamplingSerumSulfurSulofenurTherapeuticTranslatingTranslationsUntranslated RNAWalkingWorkcirculating microRNAcytochrome c oxidaseimprovedindividualized medicinemRNA Expressionmitochondrial dysfunctionnormoxianoveloperationpotential biomarkerrespiratoryscaffoldtherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Peripheral artery disease (PAD) affects 8.5 million of Americans over 40 years of age. Recent evidence from out
work and others suggest the central role of oxidative stress in the pathophysiology of PAD and its association
with greater walking impairment and decline in quality of life. Few therapeutic treatments can improve walking
distances and quality of life in PAD patients. A new emerging therapeutic approach for PAD is the usage of
mircroRNAs (miRs). miRs are endogenous 21∼25 nucleotides noncoding RNA, that can regulate
posttranscriptional gene expression. The most common mechanism of action of miRs is by binding to the 3' un-
translated region of a target mRNA and thereby reducing mRNA expression or protein translation. Circulating
miRNAs, represent potential biomarkers for the diagnosis and prognosis of PAD and a starting point for
individualized treatment. Recent evidence in PAD and hindlimb ischemia models have identified miR-210 as a
master regulator of gene expression under hypoxic conditions. Preliminary work from our laboratory has
demonstrated that miR-210 in the serum and gastrocnemius samples is increased and positively correlated with
disease progression. Furthermore, we have identified that revascularization operations can decrease circulating
miR-210 in the serum of PAD patients six-months after the operation. It has been shown that miR-210 can
negatively regulate mitochondrial respiratory activity and increase reactive species generation by inhibiting the
ISCU (iron-sulfur cluster scaffold homolog) and COX10 (cytochrome c oxidase assembly protein). Thus, our
central hypothesis, is that miR-210 gene expression is a master regulator of oxidative stress and is associated
with mitochondrial dysfunction, oxidative metabolism, walking function and quality of life.
Aim #1: miR-210 gene expression in the gastrocnemius and serum of patients with PAD, is different than healthy
age matched controls, and correlates with oxidative stress, oxidative metabolism, mitochondrial function, walking
function and quality of life.
Aim #2: Endovascular and open bypass revascularization procedures can regulate oxidative stress by
decreasing miR-210 expression in the gastrocnemius and serum of PAD patients and improve mitochondrial
function, oxidative metabolism, walking function and quality of life.
Aim #3: Utilize in-vitro studies in a novel normoxia/hypoxia/hyperoxia model of PAD to determine the extent to
which gene expression changes by inducing/inhibiting miR-210 gene expression and its interactions with mRNA
expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
-
批准号:10393061
-
项目类别:
-
资助金额:$59.41万
-
财政年份:2019
-
负责人:Panagiotis Koutakis
-
依托单位:
The role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
-
批准号:10248614
-
项目类别:
-
资助金额:$58.84万
-
财政年份:2019
-
负责人:Panagiotis Koutakis
-
依托单位:
The role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
-
批准号:10817332
-
项目类别:
-
资助金额:$14.51万
-
财政年份:2019
-
负责人:Panagiotis Koutakis
-
依托单位:
The role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
-
批准号:10589791
-
项目类别:
-
资助金额:$58.48万
-
财政年份:2019
-
负责人:Panagiotis Koutakis
-
依托单位:
The Role of microRNA-210 in regulating oxidative stress in patients with peripheral artery disease
-
批准号:9803265
-
项目类别:
-
资助金额:$65.09万
-
财政年份:2019
-
负责人:Panagiotis Koutakis
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: